You are here
CERID Bibliography
Export 48 results:
Author Title [ Type] Year Filters: Keyword is Trypanosoma cruzi [Clear All Filters]
Adenosine analogues as inhibitors of Trypanosoma brucei phosphoglycerate kinase: elucidation of a novel binding mode for a 2-amino-N(6)-substituted adenosine. J Med Chem. 2000 ;43(22):4135-50.
. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J Med Chem. 2001 ;44(13):2080-93.
Advances in Chagas disease drug development: 2009-2010. Curr Opin Infect Dis. 2010 ;23(6):609-16.
. Antigens of Trypanosoma cruzi that mimic mammalian nervous tissues: investigations of their role in the autoimmune pathophysiology of chronic Chagas' disease. Res Immunol. 1991 ;142(2):151-6.
. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci U S A. 2003 ;100(25):15149-53.
. Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. Mol Biochem Parasitol. 2003 ;132(2):75-81.
. Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. Mol Biochem Parasitol. 2002 ;122(2):181-8.
. Coculture of human peripheral blood mononuclear cells with Trypanosoma cruzi leads to proliferation of lymphocytes and cytokine production. J Immunol. 1992 ;148(1):239-48.
. Confirmation of Chagas' cardiomyopathy following heart transplantation. Heart Vessels. 2006 ;21(5):325-7.
. Crystal structures of trypanosomal histidyl-tRNA synthetase illuminate differences between eukaryotic and prokaryotic homologs. J Mol Biol. 2010 ;397(2):481-94.
Detection of live Trypanosoma cruzi in tissues of infected mice by using histochemical stain for beta-galactosidase. Infect Immun. 1999 ;67(1):403-9.
. The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth. Mol Biochem Parasitol. 1998 ;94(1):87-97.
. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother. 1996 ;40(11):2592-7.
. Engineering cytokine secretion from Trypanosoma cruzi. Mem Inst Oswaldo Cruz. 1994 ;89(4):650-1.
. Evaluation of recombinant trypomastigote surface antigens of Trypanosoma cruzi in screening sera from a population in rural northeastern Brazil endemic for Chagas' disease. Acta Trop. 1992 ;50(3):259-66.
. Experimental chemotherapy and approaches to drug discovery for Trypanosoma cruzi infection. Adv Parasitol. 2011 ;75:89-119.
. Expression of mammalian cytokines by Trypanosoma cruzi indicates unique signal sequence requirements and processing. Mol Biochem Parasitol. 1995 ;75(1):25-31.
. Expression of Trypanosoma cruzi surface antigen FL-160 is controlled by elements in the 3' untranslated, the 3' intergenic, and the coding regions. Mol Biochem Parasitol. 1999 ;102(1):53-66.
. Fl-160. A surface antigen of Trypanosoma cruzi that mimics mammalian nervous tissue. J Exp Med. 1989 ;169(3):641-52.
. The FL-160 genes of Trypanosoma cruzi are dispersed on multiple chromosomes. Exp Parasitol. 1995 ;80(3):578-82.
. FL-160 proteins of Trypanosoma cruzi are expressed from a multigene family and contain two distinct epitopes that mimic nervous tissues. J Exp Med. 1993 ;178(2):681-94.
. Humoral and cellular immune response of adults from northeastern Brazil with chronic Trypanosoma cruzi infection: depressed cellular immune response to T. cruzi antigen among Chagas' disease patients with symptomatic versus indeterminate infection. Am J Trop Med Hyg. 1993 ;49(3):370-82.
. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob Agents Chemother. 1998 ;42(12):3245-50.
. Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents. Bioorg Med Chem Lett. 2009 ;19(23):6582-4.
. LYT1 protein is required for efficient in vitro infection by Trypanosoma cruzi. Infect Immun. 2001 ;69(6):3916-23.
.